[
  {
    "ts": null,
    "headline": "Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation",
    "summary": "Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R",
    "url": "https://finnhub.io/api/news?id=32d85faaa58a6635ee64ec3b91f53fecdd6ec618ee49579c9d5b331001d40e2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759948260,
      "headline": "Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation",
      "id": 137013124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R",
      "url": "https://finnhub.io/api/news?id=32d85faaa58a6635ee64ec3b91f53fecdd6ec618ee49579c9d5b331001d40e2f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bc05e2438fe5ce184c4b91fbfc024a6ac87a029610f0c510add13a3c3db77063",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759941960,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 137083656,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bc05e2438fe5ce184c4b91fbfc024a6ac87a029610f0c510add13a3c3db77063"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment",
    "summary": "Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment",
    "url": "https://finnhub.io/api/news?id=7498fbd7f9d6844f659616dd59387c1464a3722b9c32b9ce33d9b63cfd8d68ba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759939440,
      "headline": "Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment",
      "id": 137083657,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment",
      "url": "https://finnhub.io/api/news?id=7498fbd7f9d6844f659616dd59387c1464a3722b9c32b9ce33d9b63cfd8d68ba"
    }
  },
  {
    "ts": null,
    "headline": "Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics",
    "summary": "The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors, and an aging population, underscoring the urgent need for early detection and innovative treatments. Breakthroughs in immunotherapy and targeted treatments, such as immune checkpoint inhibitors, are transforming care strategies. Public awareness initiatives enhance early d",
    "url": "https://finnhub.io/api/news?id=c32ba4d6b06080971780201d1de62e3d9cbddbb82a9ae9b1522c6f90d923c920",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759914720,
      "headline": "Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics",
      "id": 137010077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors, and an aging population, underscoring the urgent need for early detection and innovative treatments. Breakthroughs in immunotherapy and targeted treatments, such as immune checkpoint inhibitors, are transforming care strategies. Public awareness initiatives enhance early d",
      "url": "https://finnhub.io/api/news?id=c32ba4d6b06080971780201d1de62e3d9cbddbb82a9ae9b1522c6f90d923c920"
    }
  }
]